Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

BILR 355 is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) under clinical development for the treatment of human immunodeficiency virus infection, particularly in those who harbor virus resistant to the currently available NNRTIs. Two single-center, double-blinded, placebo...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Huang, Fenglei, Koenen-Bergmann, Michael, MacGregor, Thomas R., Ring, Arne, Hattox, Susan, Robinson, Patrick
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology (ASM) 2008
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2592860/
https://ncbi.nlm.nih.gov/pubmed/18824608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00363-08
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky